Drug Watch

The latest on the biggest pipeline moves.

Dermavant announced positive results from its pediatric maximal usage study.

BLA submission is based on phase 3 trial results evaluating the safety and efficacy of lebrikizumab.

Brexogen Inc.’s exosome therapy is the first entry of a clinical trial of exosome treatment for atopic dermatitis.

Alphyn Biologics’ study of AB-101a also evaluates patients who suffer from bacterial infections associated with atopic dermatitis.

Sanofi and Regeneron’s dupliumab will provide relief to patients with extreme itch and skin lesions.

Arcutis Biotherapeutics announced positive results from the ARRECTOR phase 3 trial.

TMB-001 showed positive results in the reduction of congenital ichthyosis severity in a phase 2b CONTROL study.

Boehringer Ingelheim’s first treatment option for adults will help manage burdensome flares.

INTEGUMENT-1 and 2 trial data for atopic dermatitis are expected at the end of 2022.

MediWound’s new burn care therapy alleviates risks associated with surgical debridement.